We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...

Pfizer PFE reported fourth-quarter earnings ahead of our expectations, largely due to lower-than-expected research and development spending. However, we don’t expect this will continue, so there is no ...

・Pfizer provides Covid vaccine called Comirnaty in addition to an antiviral medication used to treat COVID-19 called Paxlovid. ・In 2026, the company expects the revenue to fall further or stay at 2025 ...

GSK Plc and Pfizer Inc. are on pace to sell a combined $2 billion of their new RSV vaccines for older adults this year, more than five times what analysts had expected, according to Bloomberg ...

There are actually two factors to consider in the current drawdown. The first is the massive stock price spike that occurred during the coronavirus pandemic. Pfizer was one of a small number of ...

Activist investor Starboard Value has amassed a $1 billion stake in Pfizer, according to a report, with a turnaround in its sights. The pharmaceutical company has been struggling postpandemic to ...

Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. That kind of price decline doesn't happen by accident, which means you need to carefully ...

President Biden has promised enough vaccines for every U.S. adult by the end of May. That's enough for 300 million people. But before manufacturers can help Biden fulfill that promise, Pfizer and ...

LONDON (Reuters) - It's been a bad month for Pfizer's research labs but its head of R&D says the world's biggest drugmaker is on track to hit earlier targets for new drug filings despite the setbacks.